TC
CHRS icon

Tejara Capital’s Coherus Oncology CHRS Stock Holding History

Tejara Capital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-698,770
Closed -$511K – 55
2025
Q2 		$511K Buy
698,770
+11,552
+2% +$9.97K 0.24% 64
2025
Q1 		$555K Sell
687,218
-50,940
-7% -$58.6K 0.21% 68
2024
Q4 		$1.02M Sell
738,158
-220,206
-23% -$247K 0.67% 35
2024
Q3 		$997K Sell
958,364
-72,022
-7% -$98.8K 0.47% 46
2024
Q2 		$1.78M Sell
1,030,386
-25,000
-2% -$50.3K 0.65% 40
2024
Q1 		$2.52M Buy
+1,055,386
New +$2.6M 0.93% 32

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Tejara Capital's CHRS Position: Q3 2025 in Review

Tejara Capital sold out of Coherus Oncology (CHRS) in Q3 2025, closing a stake of 698,770 shares — an estimated $511K sold.

Tejara Capital first reported a position in CHRS in Q1 2024 and held it in 6 quarters. The position peaked at $2.52M in Q1 2024. 114 funds tracked by Wall St. Rank hold CHRS as of Q3 2025.

  • Tejara Capital reported no remaining Coherus Oncology position as of Q3 2025 after selling out during the quarter.
  • Tejara Capital sold 698,770 Coherus Oncology shares in Q3 2025, an estimated $511K.
  • Tejara Capital first reported a position in Coherus Oncology in Q1 2024 and held it in 6 quarters.
  • Tejara Capital's Coherus Oncology position peaked at $2.52M in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2025.

Based on Tejara Capital's 13F filing for Q3 2025, filed 4 Nov 2025.